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Abstract
Background: Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is common due to shared routes
of transmission, as reported approximately 10% of 33 million HIV-infected patients worldwide are chronically infected with HBV.
Mutations of HBsAg especially within the “a” determinant could alter the antigenicity of the protein, causing failure of HBsAg neu-
tralization and escaping from the host’s immune system. This results in active viral replication and liver disease.
Objectives: The aim of the survey was to identify HBV genotype and subtype, and different mutations in HBV S gene in hepatitis B
patients co-infected with HIV in Iran.
Methods: PCR performance and HBV-DNA extraction from plasma of 124 samples obtained from treatment naive HIV/HBV co-
infected participants were according to the protocol. Direct sequencing and alignment of surface gene were carried out using ref-
erence sequences from the Gene Bank database.
Results: From 124 HIV/HBV ELISA positive samples, 40 were HBV DNA-positive. The mean age of patients was 33.88 years. 20% of them
were female and 80% were male. All isolates belonged to the sub genotype D1/ayw2 and genotype D. There were 50 point mutations
including 23 (46%) missense and 27 (54%) silent mutations in amino acid level. Twenty three amino acid mutations occurred in
different immune epitopes such as 11 (47.82%) in B cell, 6 (26.08%) in T helper and 2 (%8.6) in CTL. The prevalence of mutations in both
“a” determinant region and Major Hydrophilic Region (MHR) was 5 (21.73%).
Conclusions: Our findings showed that P127T and A70P (Outside of MHR) were the most frequently occurring substitution muta-
tions. P127T, P132T, G130R, and S136Y substitutions placed in the first loop of the “a” determinant and the other substitutions of P142T
and D144N occurred in the second loop of “a” determinant. The results of our study showed that most of the mutations occurred in
B cell epitopes. The mutation in a surface gene of HBV may be selected by immune pressure or anti-retroviral therapy.
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1. Background
About 350 - 400 million individuals have chronic hep-
atitis worldwide; in other words, 5% of individuals all
around the world are chronic carriers of hepatitis B virus
(HBV). Thus, this infection represents a worldwide public
health problem (1). Co-infection with HIV augments the
risk of HBV chronicity, development of liver cirrhosis, and
hepatocellular carcinoma (2). Hepatitis B viruses are classi-
fied into nine serotypes (ayw1, ayw2, ayw3, ayw4, ayr, adw2,
adw4, adrq+, and adrq) and ten genotypes (A-J) (3). The po-
sition located in HBsAg at codon 124 to 147 within the ma-
jor hydrophilic region (MHR) is named “a” determinant.
This region of the HBs surface antigen stimulates the pro-
duction of anti-HBs antibodies during the course of the ini-
tial immune response. The structure of “a” determinant is
made of two loops that link together with disulfide bonds
in amino acids 124/137 and 139/147; this is defined as a major
B-cell epitope which is highly conserved (4). The substitu-
tion at codon 145 in “a” determinant region affects the anti-
genicity of the surface gene and leads to a defeat in neutral-
ization of HBs antigen by anti-HBs antibody. This results in
the escape from the host immune response.
The mutations of HBV can emerge in patients following
pressure selection from either immune response or treat-
ment options. Compared to wild-type viruses, mutations
that fall out of the immunodominant epitopes of hepatitis
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B virus surface antigen are at undetectable levels. In some
immunoassay tests, HBsAg mutants have been shown as
false-negative results (5). Co-infection of HBV in HIV posi-
tive patients is common and estimated to be 5% - 15% (6).
Co-infection with HIV augments the risk of HBV chronic-
ity, development of liver cirrhosis, and hepatocellular car-
cinoma (HCC) (7). HIV infection has a substantial impact
on the natural promotion of HBV infection, with increased
levels of HBV DNA and high rate of liver- associated mortal-
ity (8).
HIV infection has a severe effect on the outcome of
chronic viral hepatitis infections, and the management
of these co-infected patients confronts many problems.
Chronic hepatitis in HIV-positive individuals may occur
due to HBV and HCV. The highest mortality is reported
among multiple hepatitis compared to alone infection
(9). Treatment during HIV/HBV co-infection leads to a de-
crease in symptoms and virus circulation of HBV DNA and
HIV RNA. The accumulated mutations during the natural
course of HBV have been shown in a selected manner and
may be responsible for the reactivation (10). The most com-
mon HBV S gene mutations in HIV positive patients are
L175S, V164E, I103T, F134V, D144E, M133I, and K122R.
2. Objectives
The aim of this study was to determine the genotype
and subtype of hepatitis B virus and HBV S gene mutations
in patients co-infected with HIV.
3. Methods
This study conducted on one hundred twenty four pa-
tients with confirmed HIV/ HBV co-infection, who had been
referred by specialist for HBV infection diagnosis to virol-
ogy diagnostic laboratory of Golestan University of Med-
ical Sciences. None of the patients were vaccinated for
HBV or had a history of immunoglobulin therapy; all pa-
tients were negative for antibodies against hepatitis C and
hepatitis D viruses. Collection of samples was from May
to August 2014 after approval of the study by the univer-
sity ethics committee. Prior to tests being carried out, the
patient’s consent was obtained. Blood samples were col-
lected in anti-coagulant EDTA 5% and plasma was sepa-
rated and used for further examination. All patients were
tested for serological marker of HBV (HBsAg) using com-
mercial ELISA kit (from ACON Biotech Hangzhou, China).
All the samples were HBsAg positive.
3.1. DNA Extraction and Primer Design
Extraction of HBV-DNA was performed using High Pure
Viral Nucleic Acid Kit (Roche, Hamburg, Germany). 200µL
of plasma was tested for each sample according to manu-
facturer’s recommendations and then stored at - 20°C for
PCR. Appropriate primers were used to amplify the S gene
with maximum sensitivity for HBSAg and the first loop of
“a” determinant. The length of applicant was 482 bp and
PCRs were performed with a forward primer (5’ CTA GAC
TCG TGG TGG ACT TCT C -3’) and reverse primer (5’ AAG CCA
NAC ART GGG GGA AAG C 3’), corresponding to nucleotide
position 250 - 732 (3).
3.2. PCR, DNA Sequencing andMutation Analysis
100 ng of DNA extraction was added to an amplifica-
tion mixture including 1X PCR buffer, 2.5 Mm of MgCl2, 0.1
Mm dNTP mix, 2.5 U of TaqDNA polymerase (QIAGEN, Ham-
burg, Germany), and 0.2 pmol/µL of each primer in a to-
tal volume of 50 µL with distilled water. The PCR program
consisted of 5 minutes denaturation at 94°C, 30 cycles of
amplification including denaturation for 20 Sec at 94°C,
primer annealing for 30 Seconds at 60°C, and extension
for 40 Seconds at 72°C, with a final extension at 72°C for 5
minutes. PCR products were analyzed by 1.5% agarose gel
electrophoresis and stained with ethidium bromide. Di-
rect sequencing was performed to positive PCR products
(Macro gene, South Korea) and surface gene was aligned
using standard hepatitis B sequence [Accession number:
AB033559 and GU938305] from the gene bank database.
Amino acid mutations were determined using blast, gene
runner, and chromas programs.
4. Results
In this study, 8 (20%) participants were female, with
a mean age of 33.88 years. A minority of the patients
(10%) were HBeAg positive. The results of reference se-
quence revealed that all sequences belonged to genotype
D, subgenotype D1, subtype ayw2. In the Amino acid muta-
tion level, our results showed the occurrence of 50 point
mutations composed of 23 mutations (46%) as missense
(amino acid altering) and 27 mutations (%54) as silent. Our
findings also showed that P127T and A70P were the most
frequently occurring substitution mutations, as shown in
Figure 1. Based on statistical analysis in SPSS, there was no
significant association between the age and sex of patients
and the patterns of amino acid substitution. P127T, P132T,
G130R, and S136Y substitutions placed in the first loop of
the “a” determinant and the other substitutions of P142T
and D144N occurred in the second loop of “a” determinant.
4.1. Amino Acid Substitutions Within the HBS Ag Immune Epi-
topes
Out of 23 amino acid mutations which occurred in
different immune epitopes within the surface Antigen, 11
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Table 1. Baseline Characteristics of all HIV/HBV Co-Infected Individuals Based on HBV
Genotypes
Variable Total HIV/HBV Patients Genotype
Patients, n (%) 124 D
Age, years,mean (IQR) 33.88 D
Male sex, n (%) 80% D
CD4+ T-cell count, cells/mm3 ,
median (IQR)
130 - 220 D
HBeAg positive, n (%) 10% D
HBVDNA, log10IU/mL,median
(IQR)
5.7 (2 - 7.65) D
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Figure 1. The Frequency and Distribution of Amino Acid Substitutions in the
HIV/HBV Patients
(47.82%) occurred in B cell epitope, 6 (26.08%) in T- helper,
and 2 (%8.6) in CTL epitopes (Table 2).
The phylogenetic tree was drawn using the “maximum
likelihood” method with bootstrap test (500 replicates).
The strains were classified into two clusters A and B. The
type A included 12 isolates with 78% similarity divided into
two sub-groups I and II. Two isolates S151 F and S64 F are
distant members of other isolates belonging to this group.
The two species KU212155.1 and KJ810962.1 are sister taxa.
There are two sub-groups in type B that were separated
with a value of 49%. In sub-group II, s68F, s89F, and S98F
had 79% similarity and more distant from other species.
5. Discussion
The comparison of sequences found in this study
with the gene bank standard sequence [Accession num-
ber: AB033559] and achieved Iranian sequences [Accession
number: GU938305] showed all isolates belonged to the
genotype D, sub-genotype D1, and subtype ayw2. Based
on the results, our study is comparable with other stud-
ies conducted in Iran that found Genotype D, sub-genotype
D1, and subtype ayw2 are accounted for 100% of isolates
(Hamkar et al., (11) Norouzi et al. (12).
We found a few mutations at codons 122 (15%) and 160
(0%), which are known to dictate the d/y and w/r subtypic
determinants. This is similar to the reports that indicate
subtype-specific positions are supposed to be tolerant to
random mutations (13). Some substitutions are able to
defect the binding of neutralizing antibodies to the HBV
surface antigen especially in “a” determinant region. Mu-
tations that occur in this area include P127T, S136Y, P142T;
D144N causes structural changes in the antigenicity of the
surface gene and affects the affinity of antibodies. Viruses
carrying mutations in T-cell epitopes cannot be recognized
by specific T-cells of an individual, and anti-HBs production
will not enhance in this group of patients (14). The muta-
tion of Th and CTL epitopes in these patients indicates an
ineffective T cell immune response.
In comparison with other immune epitope mutations
in this study which distributed in different residues, the
mutations of 2 CTL epitope altered in only 2 amino acid
residues, suggesting a poor centralization of immune se-
lection pressure at a hot spot position in this selection. It
has already been shown that these responses are weak and
sometimes the immune system is weakened during co-
infection of HIV/HBV due to the absence of selective pres-
sure that causes the virus to undergo a mutation (10). In
a previous study, Huang et al. (2004) (15) found that mu-
tations at amino acid positions 135, 126, 136, 145, and 129 of
“a” - determinant occur in conjunction with the absence of
detectable anti HBsAg in samples from Qidong in China (1).
Some studies have shown co-infection with HBV may
be associated with a more progression course of HIV dis-
ease. Brown et al. (16) showed mutations within the “a”
determinant during the natural history of infection are
significantly observed within the first loop (aa 107 to 138),
whereas those induced under immune pressure due to ac-
tive and /or passive immunization are more frequently ob-
served within the second loop (aa 139 to 147).
In our study, mutations of the P127T, G130R, P132R, and
S136Y in the first loop and mutations of P142T and D144N in
the second loop were observed (2). Similar mutations have
been reported in the study of Kamili (17). G145R mutation
was detected neither in our study nor in the study of Julie
Sheldon in 2007 (4). However, we detected substitution
A70P, P127T, and S136Y in the current study more frequently
in HIV co-infected patients with genotype D. We compared
the results of mutations in the S gene of HBV between
co-infected HIV/HBV and mono-infected HBV chronic pa-
tients. The comparison showed that the co-infections of
HIV/HBV had fewer mutations than mono-infections. This
may be due to the weakness of the immune system and ab-
sence of selective antibody pressure in these patients. Sev-
eral studies have shown that some genotypes of hepatitis
related to severe hepatic diseases. Hepatitis B virus geno-
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Table 2. Mutations in Antigenic Epitopes of HBV S Gene
Mutation HLA Restriction Cell Subsets Sequence
- B 100 - 160
P142T, G159R, G112R Class II Th (CD4) 160 - 100
C149S, P127 T,S136Y,S136Y Class II Th (CD4) 100 - 160
R122T,T118A,G130R Class II Th (CD4) 100 - 160
V176L,S174N Class I CTL 171 - 179
V176L, W182G,V184E Class I HLA-A2 175 - 184
T189L,S139K, T189M,P188H Class II Th (CD4) 197 - 186
 
2
65
86
87
S14 F
49
65
S68 F
S89F
S51F
S64 F
S151 F
79
49
S98 F
0.002
S10 F
S18 F
GQ486614.1 Hepatitis B virus isolate GS579 polymerase (p0l) gene partial cds (7)
KC339865.1 Hepatitis B virus isolate IR-95 large S protein (S) gene complete cds(3)
KU212155.1 Hepatitis B virus isolate CbaArgBD 16 surface antigen (S) and polyrtierase (P) genes partial cds
KJ810962.1 Hepatitis B virus isolate IC 29 S protein (S) gene partial cds
KC875297.1 Hepatitis  B virus isolate HBV84 genotype D complete genome
KT275280.1 Hepatitis B virus isolate EPA 183 polyrnerase (P) gene partial cds and S protein (S) gene partial cds alternatively spliced
KF631301.1 Hepatitis B virus isoIate 75 reverse transcriptase gene partial cds
Figure 2. Phylogenetic Analysis of the HBV Isolates Circulating Among the HIV/HBV Co-Infected Population in Iran
types A and D are prevalent in chronic liver disease patients
of Indian origin; and HBV genotype D is associated with
more severe diseases and may predict the occurrence of
HCC in young patients. Future research should focus on
determining the clinical significance of the different HBV
genotypes and mutations found in this population.
5.1. Conclusion
Mutations in the HBsAg of HBV/HIV co-infected pa-
tients presumably may be an ordinary exhibition, which
might have some implications, eventually leading to the
progression of chronicity, cirrhosis, and hepatocellular
carcinoma in hepatitis B virus infection. The global fre-
quency of MHR mutations is 27.8%. The frequency of MHR
mutations for chronic carriers was 24% in Japan, up to 28%
in Taiwan (18), close to 40% in Spain (19), and 50% in Ko-
rea (20). This frequency was 21.73% in our study compared
to a global range of mutation in the MHR region of the
HBV S gene. This study showed the frequency of muta-
tions in MHR region similar to the prevalence of MHR mu-
tations reported from other parts of the world. Our results
showed that HBV surface gene sequencing and genotyp-
ing may be promising to treat patients effectively with an-
tiviral chemotherapy for chronic hepatitis B in patients co-
infected with HIV.
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Table 3. Amino Acid Mutations Between Patients with HIV/HBV Co-Infection and Patients with Chronic HBV
Region Common Amino Acid Substitutions Co Infection Mono Infection
B cell N131T, I133M, H134Y, R159G, N140T, I117S, S120P, T122R,
F114S, R109L, L110I, R112G
R159G, ,T122R,R112G N131T, I133M, H134Y, R159G, N140T, I117S, S120P, T122R,
F114S, R109L, L110I, R112G
TH cell L62P, S65C, L80F C83F, C85F, M87L I89L, T92I, A96V,
R186L, L189T G190V, A191W Y192L
L189T L62P, S65C, L80F, C83F, C85F, M87L, I89L, T92I, A96V,
R186L, L189T, G190V, A191W, Y192L
T CELL N174S, L177V N174S N174S, L177V
Adeterminant N131T, R133M, I133M, H134Y, N140T S136Y, D144N ,G130R, P132T, P142 ,P127T N131T, R133M, I133M, H134Y, N140T
MHR Y100F, L109R, I110L, G112R, S117I, P120S/T, R122K/T,
M133I, Y134H, T140I, S143L, G145R, G159R, E164V
G112R,R122T, G159R Y100F, L109R, I110L, G112R, S117I, P120S/T, R122K/T,
M133I, Y134H, T140I, S143L, G145R, G159R, E164V
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